Lung cancer (LCa) remains the leading cause of cancer-related mortality worldwide,
with late diagnosis and limited therapeutic approaches still constraining patient’s outcome. In recent years,
liquid biopsies have significantly improved the disease characterization and brought new insights into
LCa diagnosis and management. The integration of microfluidic devices in liquid biopsies have shown
promising results regarding circulating biomarkers isolation and analysis and these tools are expected to
establish automatized and standardized results for liquid biopsies in the near future. Herein, we review the
status of lab-on-a-chip approaches for liquid biopsies in LCa and highlight their current applications for
circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) research and clinical validation studies. READ ARTICLE
Cancers DOI:10.3390/cancers13092101
Authors: Carvalho, Â., Ferreira, G., Seixas, D., Guimarães-Teixeira, C., Henrique, R., Monteiro, F.J., Jerónimo, C.
